{"id":"on-01910-na","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1241855","moleculeType":"Small molecule","molecularWeight":"451.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MDM2 is a negative regulator of the p53 tumor suppressor protein. By inhibiting MDM2, ON 01910.Na can increase p53 levels and induce apoptosis in cancer cells.","oneSentence":"ON 01910.Na is a small molecule that targets the MDM2 protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:14.286Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT03786237","phase":"PHASE1, PHASE2","title":"Rigosertib for RDEB-SCC","status":"COMPLETED","sponsor":"Prof. Johann Bauer","startDate":"2021-04-12","conditions":"Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma","enrollment":2},{"nctId":"NCT04177498","phase":"EARLY_PHASE1","title":"Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2021-08-24","conditions":"Recessive Dystrophic Epidermolysis Bullosa","enrollment":3},{"nctId":"NCT05764395","phase":"PHASE2","title":"Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors","status":"SUSPENDED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2023-05-09","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":29},{"nctId":"NCT04263090","phase":"PHASE1, PHASE2","title":"Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-06-29","conditions":"Non-small Cell Lung Cancer, Adenocarcinoma, Stage IV","enrollment":25},{"nctId":"NCT02562443","phase":"PHASE3","title":"Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA","status":"TERMINATED","sponsor":"Traws Pharma, Inc.","startDate":"2015-12-02","conditions":"Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts","enrollment":372},{"nctId":"NCT01926587","phase":"PHASE1, PHASE2","title":"Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2013-08","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":45},{"nctId":"NCT01904682","phase":"PHASE2","title":"Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2013-07","conditions":"Myelodysplastic Syndromes","enrollment":45},{"nctId":"NCT02730884","phase":"PHASE2","title":"Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-16","conditions":"Leukemia, Myelofibrosis, Anemia","enrollment":3},{"nctId":"NCT02075034","phase":"PHASE1","title":"Three Dosing Schedules of Oral Rigosertib in MDS Patients","status":"WITHDRAWN","sponsor":"Traws Pharma, Inc.","startDate":"2014-05","conditions":"Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT01241500","phase":"PHASE3","title":"Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2010-11","conditions":"Myelodysplastic Syndromes, MDS, RAEB","enrollment":299},{"nctId":"NCT01928537","phase":"PHASE3","title":"Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2013-08","conditions":"Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia","enrollment":67},{"nctId":"NCT00987584","phase":"","title":"Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk","status":"COMPLETED","sponsor":"Peter L Greenberg","startDate":"2009-06","conditions":"Myelodysplastic Syndromes","enrollment":13},{"nctId":"NCT00533416","phase":"PHASE1","title":"Safety of ON 01910.Na in Patients With Myelodysplasia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2007-09-14","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT00861510","phase":"PHASE1","title":"A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-03-05","conditions":"Lymphoma, Mantle-cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Hairy Cell","enrollment":16},{"nctId":"NCT00854646","phase":"PHASE1","title":"Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2008-10","conditions":"Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":22},{"nctId":"NCT00856791","phase":"PHASE2","title":"Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2009-03","conditions":"Ovarian Cancer","enrollment":1},{"nctId":"NCT00854945","phase":"PHASE1, PHASE2","title":"Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2009-01","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT00906334","phase":"PHASE2","title":"Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2009-05","conditions":"Myelodysplastic Syndrome","enrollment":14},{"nctId":"NCT01167166","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2010-07","conditions":"Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease","enrollment":30},{"nctId":"NCT01807546","phase":"PHASE2","title":"Oral Rigosertib for Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2013-03","conditions":"Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma","enrollment":64},{"nctId":"NCT01584531","phase":"PHASE2","title":"Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2012-05","conditions":"Myelodysplastic Syndrome, MDS, Trisomy 8","enrollment":82},{"nctId":"NCT01538537","phase":"PHASE1","title":"Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2006-08","conditions":"Advanced Cancer, Solid Tumors, Cancer","enrollment":29},{"nctId":"NCT01048619","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2009-12","conditions":"Myelodysplastic Syndrome","enrollment":36},{"nctId":"NCT01538563","phase":"PHASE1","title":"Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2006-06","conditions":"Solid Tumors, Advanced Cancer, Cancer","enrollment":42},{"nctId":"NCT00861328","phase":"PHASE1","title":"Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2008-02","conditions":"Advanced Solid Tumors","enrollment":18},{"nctId":"NCT00861783","phase":"PHASE1","title":"Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2008-06","conditions":"Hepatoma, Advanced Solid Tumor","enrollment":16},{"nctId":"NCT02107235","phase":"PHASE1","title":"Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2014-01","conditions":"Head and Neck Neoplasms, Carcinoma, Squamous Cell","enrollment":2},{"nctId":"NCT00867061","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)","status":"WITHDRAWN","sponsor":"Traws Pharma, Inc.","startDate":"2009-03","conditions":"Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT01125891","phase":"PHASE1","title":"Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2009-01","conditions":"Malignant Neoplasmas, Solid Tumors","enrollment":39},{"nctId":"NCT02030639","phase":"PHASE1","title":"Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2014-01","conditions":"Healthy","enrollment":6},{"nctId":"NCT01165905","phase":"PHASE1","title":"Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2010-01","conditions":"Solid Tumor","enrollment":10},{"nctId":"NCT01168011","phase":"PHASE1","title":"Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2010-07","conditions":"Solid Tumor","enrollment":68},{"nctId":"NCT01360853","phase":"PHASE3","title":"Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2011-05","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rigosertib sodium","rigosertib","ON 01910","Sodium(E)2,4,6trimethoxystyryl-4methoxy-3glycylbenzylsulfone"],"phase":"phase_3","status":"active","brandName":"ON 01910.Na","genericName":"ON 01910.Na","companyName":"Traws Pharma, Inc.","companyId":"traws-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ON 01910.Na is a small molecule that targets the MDM2 protein. Used for Relapsed or refractory acute myeloid leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}